Compound 27: Preclinical Data for a Novel MASH Drug Candidate

Zhe Zhang published a dataset on figshare in May 2026 detailing the preclinical evaluation of a novel non-carboxylic steroidal FXR agonist, compound 27, for treating metabolic dysfunction-associated steatohepatitis (MASH). The 9.3 KB CSV file contains data from in vitro and in vivo studies, including EC50 values for FXR and TGR5 activation, oral bioavailability in rats, and efficacy results from liver fibrosis and MASH models.

Use Cases

• Modeling dose-response relationships based on reported EC50 values for FXR and TGR5.
• Comparing off-target receptor profiles based on the described MRGPRX4 activation data.
• Analyzing in vivo efficacy correlations using data from the CCl4-induced fibrosis and MASH models.
• Benchmarking pharmacokinetic parameters like oral bioavailability (F) in preclinical species.

Strengths

• Dataset includes specific, quantitative pharmacological measurements (e.g., EC50 = 10 ± 3 nM for FXR).
• Reports key preclinical results, including a 70.30% oral bioavailability in rats and in vivo efficacy data.
• Data is structured in a CSV format (9.3 KB), facilitating programmatic analysis.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for certain statistical methods.
• Description metadata is limited; actual data quality requires manual inspection after download.

Provenance

Source

Zhe Zhang via figshare

Collection Method

Likely contains experimental results from rational drug design and preclinical animal studies.

Time Range

Study period is not specified; dataset was published in 2026.

Freshness

Last updated 2026-05-08 19:06:37; freshness should be verified.

Geography

Geographic scope of the research is not specified.